CryoPort stock price target raised to $8 by Jefferies on strong Q2 results

Investing.com - Jefferies raised its price target on CryoPort (NASDAQ:CYRX) to $8.00 from $6.50 while maintaining a Hold rating following the company’s second-quarter financial results. According to InvestingPro data, the stock has experienced significant volatility, dropping over 10% in the past week, though it remains about 47% above its 52-week low of $4.58.

The firm noted that CryoPort’s second-quarter performance was "impressive," with revenues exceeding consensus expectations by 9%, driven by strength across both its Life Sciences Services (LSS) and Life Sciences Products (LSP) segments. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 5.56, though analysts anticipate a sales decline in the current year.

Despite absorbing a $2 million revenue headwind tied to SRPT in the second half of 2025, CryoPort maintained its full-year 2025 revenue guidance, which projects growth of 5-10% year-over-year.

Jefferies highlighted improved profitability metrics as the company approaches adjusted EBITDA break-even, a positive development for its operational efficiency.

CryoPort ended the second quarter with more than $400 million in cash, which Jefferies believes provides "plenty of balance sheet optionality," with the company currently favoring share repurchases ($67 million remaining in the program) over significant merger and acquisition activity.

In other recent news, CryoPort Inc. reported its second-quarter 2025 earnings, demonstrating a strong revenue performance that exceeded forecasts. The company posted earnings per share of $2.05, significantly outperforming the expected -$0.27. Revenue reached $45.5 million, surpassing the anticipated $41.74 million by 9.01%. Following these results, KeyBanc upgraded CryoPort from Sector Weight to Overweight, with a price target of $15.00. The upgrade was influenced by CryoPort’s 33% revenue growth in commercial cell and gene therapies, 28% growth in its BioStorage business, and 21% growth in Life Sciences Services. Despite these financial achievements, CryoPort’s stock experienced a decline in aftermarket trading. KeyBanc’s upgrade reflects confidence in the company’s momentum within the cell and gene therapy sector. These developments highlight CryoPort’s strong performance and potential growth in its key business areas.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.